{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-021238","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.938724+00:00","generated_at":"2026-06-22T13:36:05.205967+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ultragenyx Q3 revenue $90.7M, net loss $245.1M ($3.50) on GeneTx charge; reaffirms FY guidance","bullets":["Total revenue $90.7M (+11% YoY) driven by Crysvita $64.5M (+28% YoY) and Dojolvi $13.3M.","Net loss $245.1M vs $73.0M in Q3 2021; includes $75.2M R&D expense for GeneTx acquisition.","Cash & marketable debt securities $996.2M as of Sep 30, includes $491M from OMERS Crysvita royalty sale.","FY 2022 guidance reaffirmed: Crysvita territories $250-$260M, Dojolvi $55-$65M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-021238","json":"https://secwatch.observer/filing/0000950170-22-021238.json","markdown":"https://secwatch.observer/filing/0000950170-22-021238.md","text":"https://secwatch.observer/filing/0000950170-22-021238.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000095017022021238/0000950170-22-021238-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000095017022021238/rare-20221102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T13:36:05.205967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f9a099778f4331270c57b5722a94393ced0e3dc3","claim":"Ultragenyx Pharmaceutical Inc. reported the quarter ended September 30, 2022 results: revenue $90.7 million, net income $245.1 million, EPS $3.50 per share basic and diluted. Guidance reaffirmed.","evidence_excerpt":"Third Quarter 2022 Financial Results Net Revenues For the third quarter of 2022, Ultragenyx reported $ 90.7 million in total revenue. Ultragenyx recognized $64.5 million in Crysvita (burosumab) revenue in the Ultragenyx territories, which includes $ 51.3 million in collaboration revenue in the North American profit share territory and net product sales in other regions of $ 13.2 million. Total royalty revenue related to European Crysvita sales was $5.4 million. Dojolvi (triheptanoin) product sales in the third quarter of 2022 were $13.3 million. Mepsevii (vestronidase alfa) product sales for the third quarter of 2022 were $6.0 million. Total revenue for the third quarter of 2022 also includes $1.5 million related to technical assistance following the successful completion of technology transfer activities with Daiichi Sankyo. This compares to total revenue in the third quarter of 2021, which includes $12.1 million related to the technology transfer services which were ongoing at the ti","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017022021238/0000950170-22-021238-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$90.7 million"},{"label":"Net income","value":"$245.1 million"},{"label":"EPS","value":"$3.50 per share basic and diluted"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}